Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Colchicine cut post-MI CVD events

Key clinical point: Daily colchicine treatment cut the rate of cardiovascular disease events following an MI.

Major finding: Daily colchicine treatment cut the rate of cardiovascular disease events by 23%, compared with placebo.

Study details: COLCOT, an international, multicenter, randomized trial with 4,745 patients.

Disclosures: COLCOT received no commercial support. Dr. Tardif has received honoraria from Amarin, DalCor, Sanofi, and Servier; he has an ownership interest in DalCor; and he has received research funding from Amarin, AstraZeneca, DalCor, Esperion, Ionis, RegenxBio, Sanofi, and Servier. Dr. Lloyd-Jones had no disclosures.

Citation:

Tardif J-C et al. AHA 2019, Abstract.